HOUSTON – July 22, 2020 – The Kidney Cancer Association (KCA) is pleased to announce Sallie McAdoo, MS, joined the organization as its first Medical Director. She began her role on July 20, 2020.
“This is a new era for the KCA and we’re thrilled to have Sallie on board,” said Gretchen E. Vaughan, the KCA’s President and CEO. “Sallie will be instrumental in fulfilling our strategic objectives to take the KCA into the next phase of kidney cancer research in service of our mission to lead change and move the needle for people impacted by kidney cancer.”
As Medical Director, McAdoo will oversee all medical aspects of the KCA’s strategic research and education objectives, including scientific collaborations such as the Think Tank initiative in conjunction with the annual International Kidney Cancer Symposium and educational programs for both patients and health care professionals. McAdoo is based in the KCA’s Houston office.
“We are excited to welcome Sallie. Her deep clinical and industry knowledge and skill at building strategic partnerships will help drive our research and medical initiatives forward,” said Dr. Christopher G. Wood, Chair of the KCA’s Board of Directors and a surgeon and professor at the University of Texas MD Anderson Cancer Center in Houston, Texas.
McAdoo comes to the KCA with over a decade of experience in clinical genetics, medical affairs, and management, specializing in re-imagining existing standards to realize clinical and scientific ideas as accessible products and programs. Most recently, she was Director of Medical Affairs at Veracyte, Inc., a pioneering genomic diagnostics company. McAdoo has a BA in Biology from Edinboro University in Pennsylvania and an MS in Human Genetics and Genetic Counseling from Howard University in Washington, D.C.
“I’m very glad to be part of this dynamic team and look forward to working closely with the KCA’s Board of Directors and advisory councils, staff, and supporters to serve the kidney cancer community,” said McAdoo.
###
About the Kidney Cancer Association
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding the cure for kidney cancer. Founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, the KCA has grown into an international non-profit organization based in Houston, Texas. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.